HomeClinical TopicsCardio-PulmonaryFDA drops certain restrictive requirements for Nplate and Promacta

FDA drops certain restrictive requirements for Nplate and Promacta

The U.S. Food and Drug Administration has announced changes to the Risk Evaluation and Mitigation Strategies for Nplate (romiplostim) and Promacta (eltrombopag). Among the changes: Healthcare professionals are no longer required to complete periodic safety forms for patients either drug. In addition, healthcare professionals, hospitals, specialty care facilities, and patients are no longer required to be enrolled in the Nplate NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program or the Promacta CARES Program to prescribe, dispense or receive the drugs. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...